Joint longitudinal and time-to-event models for multilevel hierarchical data

Joint modelling of longitudinal and time-to-event data has received much attention recently. Increasingly, extensions to standard joint modelling approaches are being proposed to handle complex data structures commonly encountered in applied research. In this paper, we propose a joint model for hierarchical longitudinal and time-to-event data. Our motivating application explores the association between tumor burden and progression-free survival in non-small cell lung cancer patients. We define tumor burden as a function of the sizes of target lesions clustered within a patient. Since a patient may have more than one lesion, and each lesion is tracked over time, the data have a three-level hierarchical structure: repeated measurements taken at time points (level 1) clustered within lesions (level 2) within patients (level 3). We jointly model the lesion-specific longitudinal trajectories and patient-specific risk of death or disease progression by specifying novel association structures that combine information across lower level clusters (e.g. lesions) into patient-level summaries (e.g. tumor burden). We provide user-friendly software for fitting the model under a Bayesian framework. Lastly, we discuss alternative situations in which additional clustering factor(s) occur at a level higher in the hierarchy than the patient-level, since this has implications for the model formulation.

[1]  C. Leung,et al.  Impact of Rates of Change of Lamina Cribrosa and Optic Nerve Head Surface Depths on Visual Field Progression in Glaucoma. , 2017, Investigative ophthalmology & visual science.

[2]  Eleni-Rosalina Andrinopoulou,et al.  Bayesian shrinkage approach for a joint model of longitudinal and survival outcomes assuming different association structures , 2016, Statistics in medicine.

[3]  Andrew Gelman,et al.  The No-U-turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo , 2011, J. Mach. Learn. Res..

[4]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[5]  John B Carlin,et al.  Survival analysis with time‐dependent covariates subject to missing data or measurement error: Multiple Imputation for Joint Modeling (MIJM) , 2018, Biostatistics.

[6]  Radford M. Neal MCMC Using Hamiltonian Dynamics , 2011, 1206.1901.

[7]  Dorota Kurowicka,et al.  Generating random correlation matrices based on vines and extended onion method , 2009, J. Multivar. Anal..

[8]  Keith R Abrams,et al.  Joint longitudinal hurdle and time‐to‐event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy , 2016, Statistics in medicine.

[9]  R. Kolamunnage-Dona,et al.  Joint modelling of longitudinal and competing risks data , 2008, Statistics in medicine.

[10]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[11]  Jeffrey S. Rosenthal,et al.  Optimal Proposal Distributions and Adaptive MCMC , 2011 .

[12]  Dirk Laurie,et al.  Calculation of Gauss-Kronrod quadrature rules , 1997, Math. Comput..

[13]  S. Luo,et al.  Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease , 2014, Statistics in medicine.

[14]  S. Müller,et al.  Model Selection in Linear Mixed Models , 2013, 1306.2427.

[15]  Anastasios A. Tsiatis,et al.  Joint Modeling of Longitudinal and Time-to-Event Data : An Overview , 2004 .

[16]  J. Gabry,et al.  Bayesian Applied Regression Modeling via Stan , 2016 .

[17]  Joseph G Ibrahim,et al.  Joint modeling of survival and longitudinal non‐survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group , 2015, Statistics in medicine.

[18]  Maria Sudell,et al.  Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis , 2016, BMC Medical Research Methodology.

[19]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[20]  R. Rosenheck,et al.  Joint modelling of longitudinal outcome and interval‐censored competing risk dropout in a schizophrenia clinical trial , 2012, Journal of the Royal Statistical Society. Series A,.

[21]  M. Wulfsohn,et al.  A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.

[22]  Dimitris Rizopoulos,et al.  Joint Models for Longitudinal and Time-to-Event Data: With Applications in R , 2012 .

[23]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yongseok Park,et al.  Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models , 2013, Biometrics.

[25]  Dimitris Rizopoulos,et al.  A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time‐to‐event , 2011, Statistics in medicine.

[26]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Dimitris Rizopoulos,et al.  Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time‐to‐Event Data , 2011, Biometrics.

[28]  Graeme L. Hickey,et al.  Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues , 2016, BMC Medical Research Methodology.